It’s a new $DAWN for Day One as startup pivots to an IPO for more funding to back its work in pediatric cancer
Pediatric cancer biotech Day One Pharmaceuticals is headed for Nasdaq, in a move that comes less than three months after their work on a brain cancer treatment led to a nine-figure crossover round backed by some blue-chip investors.
The South San Francisco-based company is penciling in $100 million as their initial IPO target, though the ultimate raise will likely be higher. Tuesday’s filing comes after RA Capital led a $130 million B round for the company in February, following what CEO Jeremy Bender said at the time was “rapid” progress of their lead program.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.